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INVITED COMMENTS
Coronary revascularization prior to elective
vascular surgery: Does it reduce cardiac risk?
Debabrata Mukherjee, MD, and Kim A. Eagle, MD, Ann Arbor, Mich
Atherosclerosis is a generalized process, and patients
with peripheral vascular disease often have coexistent cor-
onary artery disease (CAD). Ashton et al1 and others have
shown that patients who require vascular surgery appear to
have an increased risk for cardiac complications because
many of the risk factors contributing to peripheral vascular
disease (eg, diabetes mellitus, tobacco use, hyperlipidemia)
are also risk factors for CAD. Another factor leading to
increased complications with vascular surgery is that major
arterial operations are time-consuming and may be associ-
ated with substantial fluctuations in extravascular fluid vol-
umes, cardiac filling pressures, systemic blood pressure,
heart rate, and thrombogenicity.2
In a selective review of several thousand vascular surgi-
cal procedures (carotid endarterectomy, aortic aneurysm
resection, and lower-extremity revascularization) reported
in the literature from 1970 to 1987, Hertzer3 found that
cardiac complications were responsible for about half of all
perioperative deaths and that fatal events were nearly five
times more likely to occur in the presence of standard
preoperative indicators of CAD.
No randomized trials of preoperative coronary revascu-
larization for the purpose of lowering perioperative risk of
noncardiac surgery have been performed, but reports of
several retrospective cohort studies have been published.
One study used an administrative database of patients who
were undergoing noncardiac surgery in the state of Wash-
ington. As compared with patients who did not undergo
percutaneous coronary intervention (PCI) preoperatively,
those who did undergo the procedure had a lower inci-
dence of perioperative cardiac complications.4 Evidence of
a potential protective effect of preoperative coronary artery
bypass grafting (CABG) comes from follow-up studies of
randomized trials and/or registries that compare medical
and surgical therapy for coronary artery disease. In a pro-
spective cohort of 246 patients with abdominal aortic an-
eurysm (AAA), Hertzer et al5 demonstrated that the cumu-
lative 5-year survival rate (75%) and cardiac mortality rate
(5%) after CABG was significantly better than the cumula-
tive survival (29%) and cardiac mortality rates (34%) in
patients with severe, uncorrected coronary involvement
(P  .0001). The investigators concluded that in selected
patients who require elective resection of AAA also war-
ranted is myocardial revascularization to enhance perioper-
ative outcomes and late survival.5 The largest study to date
included 3368 noncardiac operations performed within a
10-year period among patients assigned to medical therapy
or CABG in the Coronary Artery Surgery Study.6 Prior
successful CABG had a cardioprotective effect among pa-
tients who underwent high-risk noncardiac surgery (ab-
dominal, thoracic, vascular, or orthopedic surgery).6 The
perioperative mortality rate was nearly 50% lower in the
group of patients who had undergone CABG than in those
who received medical therapy (3.3% vs 1.7%, P  .05).
There was no difference in the outcome of patients under-
going low-risk procedures such as breast and urologic
surgery. Fleisher et al7 used Medicare claims’ data to assess
30-day and 1-year mortality after noncardiac surgery ac-
cording to the use of cardiac testing and coronary interven-
tions such as CABG and PCI within the year before non-
cardiac surgery. Preoperative revascularization significantly
reduced the 1-year mortality rate for patients undergoing
aortic surgery but had no effect on the mortality rate for
those undergoing infrainguinal surgery. Finally, an analysis
of the Bypass Angioplasty Revascularization Investigation
(BARI) evaluated the incidence of postoperative cardiac
complications after noncardiac surgery among patients
with multivessel coronary disease who were randomly as-
signed to undergo PCI or CABG for severe angina.8 At an
average of 29 months after coronary revascularization, both
groups had similar, low rates of postoperative myocardial
infarction or death from cardiac causes (1.6% in each
group). These data suggest that prior successful coronary
revascularization, when accompanied by careful follow-up,
is associated with a low rate of cardiac events after noncar-
diac surgery.8
In this issue of the Journal, Back et al evaluate the
cardiac protective effect of previous coronary revasculariza-
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tion on 425 consecutive patients before elective vascular
surgery. The authors’ data are similar to those reported
from the CASS registry6 and the Cleveland Clinic study,5
although the magnitude of risk reduction was considerably
less in the current series. There are several potential expla-
nations for this discrepancy. Overall the medical care of
individuals with vascular disease has improved recently,
with almost ubiquitous use of beta-blockers in this series.
This change would have reduced the magnitude of any
potential perioperative benefit of prior revascularization.
Previous studies have demonstrated the significant benefit
of perioperative beta-blockers in patients undergoing vas-
cular surgery.9 Other explanations for the differences be-
tween studies include the fact that this is a small retrospec-
tive population with even smaller subgroup comparisons,
which may have significantly underpowered the analysis. In
this particular series, there were significant baseline differ-
ences in the groups with and without revascularization,
which might have confounded the analysis. With significant
differences in almost every baseline characteristic, the mul-
tivariate analysis may not have been able to adjust for all
potential confounders. An important consideration to note
is that the Back et al defined recent revascularization as
CABG 1 year and PCI 6 months and prior revascular-
ization as CABG 1 to 5 years and PTCA 6 months to 1 year.
The American College of Cardiology considers patients low
risk if the patient has had complete surgical revasculariza-
tion in the past 5 years or PCI from 6 months to 5 years
previously, and if his or her clinical status has remained
stable without recurrent signs or symptoms of ischemia in
the interim.10 Approximately 15% to 20% of patients may
have re-stenosis within the 6-month period after PCI, and
this may explain the higher adverse cardiac event rate of
8.6% in those with recent revascularization vs 4.4% in those
with more distant prior revascularization in this series.
Finally, all patients with vascular disease should receive
beta-blockers perioperatively in the absence of contraindi-
cations. CABG or PCI should be limited to patients who
have a clearly defined need for the procedure that is inde-
pendent of the need for noncardiac surgery.11 This includes
patients who have poorly controlled angina despite maxi-
mal medical therapy and patients with one of several high-
risk coronary characteristics, ie, clinically significant stenosis
(50%) of the left main coronary artery, severe two- or
three-vessel coronary artery disease (70% stenosis) with
involvement of the proximal left anterior descending coro-
nary artery, easily induced myocardial ischemia on preop-
erative stress testing, and/or left ventricular systolic dys-
function at rest. Although observational studies have
provided some evidence of the benefit of perioperative
coronary revascularization, the true magnitude of the ben-
efit can be ascertained only by a well-designed prospective
randomized study, and must not only consider the imme-
diate perioperative benefits of coronary revascularization
but also the long-term impact of both functional status and
survival.
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